{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:41:20Z","timestamp":1792093280793,"version":"4.4.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Motion sickness has afflicted travelers since ancient times. Neurokinin-1 (NK1) receptor antagonists have therapeutic potential as treatments for the symptoms of motion sickness due to the widespread expression of NK1 receptors throughout important locations in the emetic pathway in the network of brainstem nuclei and the gut. This study evaluated the efficacy of tradipitant, a novel NK1 receptor antagonist, in preventing motion sickness symptoms in variable sea conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 365 adult participants with a history of motion sickness embarked on boat trips under variable sea conditions. Study participants were distributed across 34 boat trips that took place between November 2021 and April 2023 in coastal waters of the United States. Participants were randomized 1:1:1 and received 170\u202fmg tradipitant (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f120), 85\u202fmg tradipitant (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f123) or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f122). The symptoms of vomiting and nausea were evaluated with questionnaires every 30\u202fmin during the approximately four-hour trips. The primary efficacy endpoint for the study was the percentage of vomiting during vehicle travel. Statistical hypothesis testing was performed at the two-sided alpha level of 0.05 unless specified otherwise. Tests were declared statistically significant if the calculated\n                      <jats:italic>p<\/jats:italic>\n                      -value was \u2264 0.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The incidence of vomiting in both dosing arms of tradipitant was significantly lower than the placebo group across all boat trips (170\u202fmg tradipitant\u202f=\u202f18.3%, 85\u202fmg tradipitant\u202f=\u202f19.5%, placebo\u202f=\u202f44.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.0001 for both dose comparisons against placebo). Tradipitant prevented severe nausea and vomiting as compared to participants taking placebo (tradipitant\u202f=\u202f18.03%, placebo\u202f=\u202f37.70%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Tradipitant 170\u202fmg and 85\u202fmg have been confirmed to be effective in the prevention of vomiting associated with motion sickness across varied sea conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>ClinicalTrials.gov<\/jats:uri>\n                      , identifier NCT04327661.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1550670","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:20:17Z","timestamp":1741047617000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study"],"prefix":"10.3389","volume":"16","author":[{"given":"Vasilios M.","family":"Polymeropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Blake","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail R.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalise X.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas V.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane B.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail K.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos M.","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Birznieks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihael H.","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fneuro.2017.00114","article-title":"A historical view of motion sickness-a plague at sea and on land, also with military impact","volume":"8","author":"Huppert","year":"2017","journal-title":"Front Neurol"},{"key":"ref2","first-page":"371","article-title":"Motion sickness","volume-title":"Handbook of clinical neurology","author":"Golding","year":"2016"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/cns.12468","article-title":"Motion sickness: current knowledge and recent advance","volume":"22","author":"Zhang","year":"2015","journal-title":"CNS Neurosci Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"563373","DOI":"10.3389\/fneur.2020.563373","article-title":"Tradipitant in the treatment of motion sickness: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Polymeropoulos","year":"2020","journal-title":"Front. Neurol"},{"key":"ref5","first-page":"873","article-title":"Sopite syndrome: a sometimes sole manifestation of motion sickness","volume":"47","author":"Graybiel","year":"1976","journal-title":"Aviat Space Environ Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/014107687807101109","article-title":"Motion sickness adaptation: a neural mismatch model","volume":"71","author":"Reason","year":"1978","journal-title":"J R Soc Med"},{"key":"ref7","volume-title":"Motion Sickness","author":"Takov","year":"2020"},{"key":"ref8","first-page":"41","article-title":"Prevention and treatment of motion sickness","volume":"90","author":"Brainard","year":"2014","journal-title":"Am Fam Physician"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/nau.24536","article-title":"Increased risk of incident dementia following use of anticholinergic agents: a systemic literature review and meta-analysis","volume":"40","author":"Dmochowski","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1503\/cmaj.1150066","article-title":"Long-term use of diphenhydramine","volume":"187","author":"Wong","year":"2015","journal-title":"CMAJ"},{"key":"ref11","first-page":"192","article-title":"FPIN\u2019s clinical inquiries. Treatment of motion sickness","volume":"86","author":"Sutton","year":"2012","journal-title":"Am Fam Physician"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1254\/jphs.91.87","article-title":"Roles of substance P and NK(1) receptor in the brainstem in the development of emesis","volume":"91","author":"Saito","year":"2003","journal-title":"J Pharmacol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1152\/physrev.1993.73.2.229","article-title":"Neurotransmitter functions of mammalian tachykinins","volume":"73","author":"Otsuka","year":"1993","journal-title":"Physiol Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4088\/JCP.v64n0501","article-title":"The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT and the neuropharmacology of vomiting","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0165-1838(99)00092-2","article-title":"Cellular expression of the neurokinin 1 receptor in the human antrum","volume":"79","author":"Smith","year":"2000","journal-title":"J Auton Nerv Syst"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0002-9440(10)64789-X","article-title":"Substance P (neurokinin-1) and neurokinin a (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine","volume":"157","author":"Renzi","year":"2000","journal-title":"Am J Pathol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.cgh.2024.01.005","article-title":"The efficacy of Tradipitant in patients with diabetic and Idopathic gastroparesis in a phase 3 randomized placebo-controlled clinical trial","volume":"22","author":"Carlin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.gastro.2020.07.029","article-title":"Efficacy and safety of Tradipitant in patients with diabetic and idiopathic gastroparesis in a randomized, placebo-controlled trial","volume":"160","author":"Carlin","year":"2021","journal-title":"Gastroenterology"},{"key":"ref19","first-page":"115","article-title":"A questionnaire for the assessment of the multiple dimensions of motion sickness","volume":"72","author":"Gianaros","year":"2001","journal-title":"Aviat Space Environ Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.21236\/AD0768215","article-title":"Motion sickness incidence as a function of the frequency and acceleration of vertical sinusoidal motion","volume":"45","author":"O\u2019Hanlon","year":"1974","journal-title":"Aerosp Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1121\/1.395295","article-title":"Prediction of the incidence of motion sickness from the magnitude, frequency, and duration of vertical oscillation","volume":"82","author":"Lawther","year":"1987","journal-title":"J Acoust Soc Am"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/001401399185586","article-title":"Motion sickness in public road transport: passenger behavior and susceptibility","volume":"42","author":"Turner","year":"1999","journal-title":"Ergonomics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3357\/AMHP.5386.2020","article-title":"Motion sickness predictors in college students and their first experience sailing at sea","volume":"91","author":"Zhang","year":"2020","journal-title":"Aerosp Med Hum Perform"},{"key":"ref24","first-page":"1048","article-title":"Motion sickness","volume-title":"Medical aspects of harsh environments","author":"Benson","year":"2002"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e0280058","DOI":"10.1371\/journal.pone.0280058","article-title":"Validation of the motion sickness severity scale: secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness","volume":"18","author":"Czeisler","year":"2023","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/978-3-642-70479-6_9","article-title":"Mechanisms and treatment of motion illness","volume-title":"Nausea and vomiting: mechanisms and treatment. Advances in applied neurological sciences","author":"Stott","year":"1986"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/B978-1-4160-6189-2.00014-7","article-title":"Nausea and vomiting","volume-title":"Sleisenger and Fordtran\u2019s gastrointestinal and liver disease","author":"Malagelada","year":"2010"},{"key":"ref28","volume-title":"Nausea: mechanisms and management","author":"Stern","year":"2011"},{"key":"ref29","article-title":"Disorders of equilibrium","volume-title":"Clinical neurology","author":"Simon","year":"2017"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1093\/hmg\/ddv028","article-title":"Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis","volume":"24","author":"Hromatka","year":"2015","journal-title":"Hum Mol Genet"},{"key":"ref31","first-page":"166","article-title":"Research on screening methods for people susceptible to motion sickness and fatigue after long voyage","author":"Nie","year":"2021"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.7205\/MILMED-D-14-00315","article-title":"Airsickness: etiology, treatment, and clinical importance-a review","volume":"180","author":"Samuel","year":"2015","journal-title":"Mil Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3238\/arztebl.2018.0687","article-title":"The neurophysiology and treatment of motion sickness","volume":"115","author":"Koch","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1152\/physrev.1949.29.4.311","article-title":"MOTION SICKNESS","volume":"29","author":"Tyler","year":"1949","journal-title":"Physiol Rev"},{"key":"ref35","volume-title":"Scopolamine","year":"2024"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/026988110101500311","article-title":"The effects of dimenhydrinate, cinnarizine, and transdermal scopolamine on performance","volume":"15","author":"Gordon","year":"2001","journal-title":"J Psychopharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0269881113516201","article-title":"Evaluation of the effects of anti-motion sickness drugs on subjective sleepiness and cognitive performance of healthy males","volume":"28","author":"Weerts","year":"2014","journal-title":"J Psychopharmacol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1550670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:20:22Z","timestamp":1741047622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1550670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":37,"alternative-id":["10.3389\/fneur.2025.1550670"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1550670","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"1550670"}}